A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
A phase 1/2 trial of Sacituzumab tirumotecan in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) is a phase 1/2 interventional study registered as NCT06637423 by Merck Sharp & Dohme LLC, with 32 participants planned, started 2024-12-20 and due to reach its primary completion in 2029-03-14. Interventions recorded: Sacituzumab tirumotecan, Rescue medication and Supportive care measures.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.